IL2 and rheumatoid arthritis: In a prospective, open-label, Phase I to IIa study in patients with RA, low-dose IL-2 was shown to be well tolerated and effective, activating and expanding specific Tregs without activating effector T cells, thereby increasing The Treg/Teff ratio (122).